Optimizerx Corp (OPRX) valuation
Optimizerx P/E ratio history
Optimizerx trades at 38.8 times its earnings over the last twelve months and 9.7 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $12.26 | $0.27 | 45.4 | 15.1 |
| Dec 31, 2024 | $4.86 | -$1.10 | n/m | 14.1 |
| Dec 31, 2023 | $14.31 | -$1.03 | n/m | — |
| Dec 31, 2022 | $16.80 | -$0.64 | n/m | — |
| Dec 31, 2021 | $62.11 | $0.02 | n/m | — |
| Dec 31, 2020 | $31.16 | -$0.15 | n/m | — |
| Dec 31, 2019 | $10.27 | -$0.23 | n/m | — |
| Dec 31, 2018 | $10.97 | $0.02 | n/m | — |
| Dec 31, 2017 | $1.57 | — | n/m | — |
| Dec 31, 2016 | $0.81 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Optimizerx valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| OptimizerxOPRX | $175M | 38.8 | 9.7 | 1.8 |
| Sionna TherapeuticsSION | $175M | — | — | — |
| Entrada TherapeuticsTRDA | $176M | — | — | 37.6 |
| MaxcyteMXCT | $170M | — | — | 5.5 |
| InogenINGN | $186M | — | — | 0.5 |
| Pro DexPDEX | $186M | 16.0 | 18.4 | 2.3 |
| Upstream BioUPB | $186M | — | — | 58.9 |
| Akebia TherapeuticsAKBA | $190M | — | — | 0.9 |
| Cartesian TherapeuticsRNAC | $191M | — | — | 129.3 |
| Peer median | 16.0 | 18.4 | 5.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: OPRX financials · OPRX returns
No forecast, no recommendation. This page describes Optimizerx Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.